GLYcemic COntrol and OSTEOhealth: Impact of Short-Term Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

Bone damage is frequently observed in type 1 diabetes, and hyperglycemia is associated with an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims to determine whether the introduction of an automated insulin delivery (AID) system improves bone markers through rapide optimization of glycemic control. Measurements will be taken before the start of AID, 2 months and 4 months afterwards.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Age ≥ 18 years;

• Diagnosis of T1D or latent autoimmune diabetes of adults (LADA) for at least one year;

• Current HbA1c \>8.0% and high glycemic variability (CV \>36.0% using CGM);

• Participant planning to start using one of the commercially available AID;

• Anticipated use of the closed-loop mode;

• Willing to share CGM data during the study period.

Locations
Other Locations
Canada
Centre Hospitalier de l'Université de Montréal
RECRUITING
Montreal
CHUM
RECRUITING
Montreal
Contact Information
Primary
Elisabeth Nguyen
elisabeth.nguyen@ircm.qc.ca
514-987-5617
Backup
Valérie Boudreau
valerie.boudreau@ircm.qc.ca
514-987-5643
Time Frame
Start Date: 2025-02-01
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 25
Treatments
AID initiation
The participants will be selected on the basis that they are planning to start using one of the commercially available AID.~They will start treatment after the initial measurements (baseline), then repeat the measurements at 2 and 4 months post-AID.
Related Therapeutic Areas
Sponsors
Leads: Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Institut de Recherches Cliniques de Montreal, Laval University

This content was sourced from clinicaltrials.gov